Scientific and corporate news
Outcomes of adipose tissue stem cell transplantation for the treatment of refractory lupus nephritis
To date, the immunomodulatory capacity of mesenchymal stem cells is well known. In this phase one clinical trial, the efficacy of these cells for the treatment of refractory lupus nephritis (LN) was verified. Specifically, 9 patients received systemic infusion of mesenchymal stem cells derived from adipose tissue and followed up for a 12-month follow-up period.
Outcomes of mesenchymal stem cell transplantation from umbilical cord for the treatment of decompensated liver cirrhosis
group (n = 111) and cord blood mesenchymal stem cell infusion group (n = 108). Both groups were followed up for a follow-up period of 7 years (October 2010 to October 2017). Specifically, patients in the control group received only conventional therapy while patients in the other group received three infusions of mesenchymal stem cells from cord tissue at four-week intervals.
Maternal grandmother’s cells in cord blood
During pregnancy there is a physiological two-way exchange of cells between mother and foetus. Similarly, expectant mothers may have acquired cells from their mothers (GdM) and these latter cells may in turn be transferred to the fetus through the mother-fetus blood stream.
Extracellular vesicles released from cord blood mesenchymal stem cells for treatment of Alzheimer’s disease
senchymal stem cells are able to induce a therapeutic effect when transplanted into an animal model of Alzheimer’s disease. Neprilysin (NEP) is the main enzyme responsible for the degradation of amyloid (Aβ).